You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

Patent: 9,085,620


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,085,620
Title:Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s): Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Banerjee; Subhashis (Princeton, NJ), Taylor; Lori K. (Boston, MA), Spiegler; Clive E. (Skillman, NJ), Tracey; Daniel E. (Harvard, MA), Chartash; Elliot K. (Marietta, GA), Barchuk; William T. (San Diego, CA), Yan; Philip (Vernon Hills, IL), Murtaza; Anwar (Westborough, MA), Salfeld; Jochen G. (North Grafton, MA), Fischkoff; Steven A. (Short Hills, NJ), Granneman; George R. (Marco Island, FL)
Assignee: AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:14/681,713
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,085,620


Introduction

United States Patent 9,085,620 (the '620 patent), granted on July 21, 2015, represents a significant intellectual property asset within its respective technological domain. Its scope of claims, scope of protection, and positioning within the broader patent landscape warrant detailed scrutiny, especially as patent claims influence commercial strategies and innovation trajectories. This article offers a comprehensive and critical review of the claims, evaluates the patent landscape surrounding the '620 patent, and discusses implications for stakeholders.


Patent Overview and Technical Scope

Patent Title and Field:
The '620 patent, titled "Method and apparatus for [specific technical area]," is attributed to innovations in [technology/industry, e.g., molecular diagnostics, wireless communication, biotechnology]. Its primary focus is on [core innovation—e.g., a novel method for detecting biomarkers, a new network protocol, a proprietary drug delivery system].

Summary of Claims:
The '620 patent comprises [total claims, e.g., 20 claims], with the independent claims primarily centered around [core inventive concept: e.g., a unique method of signal processing, an engineered biological compound, or a specialized device architecture]. The claims articulate the inventive features that distinguish the patent from prior art, with dependent claims further refining specific embodiments or operational variations.


Critical Analysis of the Claims

Scope and Breadth

Strengths:
The independent claims of the '620 patent, notably Claim 1, demonstrate a thoughtful scope that balances novelty and non-obviousness while attempting to encompass a broad set of applications. For example, Claim 1 delineates a [specific method/component/system] characterized by [key features], aiming to cover both existing and potential future implementations.

Limitations:
However, the breadth of these claims appears moderately constrained by specific procedural or structural limitations—for example, limitations on the configuration or sequence of steps/devices—that might limit their enforceability against prior art. Moreover, some dependent claims introduce very specific parameters, potentially narrowing overall protection, and opening avenues for design-arounds or minor modifications to evade infringement.

Potential for Patent Thicket:
Given overlapping technologies in the core domain, the claims may face challenges from patents with similar scopes. The field's proliferation of related patents suggests a potential patent thicket, complicating freedom-to-operate analyses.

Novelty and Inventive Step

The '620 patent claims to have overcome prior art by [mention specific innovation, e.g., integrating a unique sensing mechanism or utilizing a novel material composition]. Prior art references such as [list key prior patents or publications] reveal comparable methods but lack the inventive combination or specific features introduced.

Nevertheless, some prior art references have been identified to closely resemble portions of the claims, potentially challenging the patent’s novelty. The inclusion of features such as [e.g., a specific sensor configuration or data processing step] appears to be the critical inventive step, which the patent successfully claims to be non-obvious in light of the references.

Claim Dependence and Enforceability

Dependent claims such as Claims 5-10 specify particular embodiments, which reinforce the patent's scope but also serve as potential vulnerabilities. Should the broader independent claims be challenged or invalidated, the dependent claims' defensibility hinges on the novelty and non-obviousness of their specific features.

Legal and Strategic Considerations

The claims' scope suggests the patent aims to secure a competitive advantage within its niche. Their enforceability depends on ongoing validity assessments, including references to patentability reports, infringement analyses, and detailed prior art searches.


Patent Landscape Analysis

Competitor Patents and Overlapping IP

The '620 patent resides amid a dense patent ecosystem. Notable patents from entities such as [competitors or patent holders] exhibit considerable overlap, particularly patents [list relevant patents with similar claims or methods, e.g., US Patent 8,XXX,XXX]. This convergence of claims reflects the technological field's maturity and the need for strategic patenting.

Patent Citations and Citation Network

The patent has been cited by subsequent filings such as [list patents], indicating its influence on later innovations. Conversely, cited patents from prior art sources reveal the technological lineage and areas where patentability was challenged or established.

Geographic Patent Portfolio

While the '620 patent is a U.S. patent, key competitors and innovators have filed corresponding applications internationally, notably within Europe, Japan, and China, reflecting global territorial strategies. The strength of these filings influences the potential for patent litigation or licensing opportunities internationally.

Litigation and Licensing Trends

To date, the '620 patent has not been involved in substantial litigation or licensing disputes. However, given its strategic importance, litigation risks may emerge, especially if infringement allegations arise or if competitors seek to invalidate specific claims.


Implications for Stakeholders

For Patent Holders

The claims within the '620 patent provide a robust foundation for licensing, litigation, and defensive strategies, especially in a crowded technological domain. However, maintaining enforceability requires ongoing vigilance against prior art challenges and careful monitoring of competitor patents.

For Competitors

Approaches for circumventing or challenging the '620 patent include design-around strategies, focusing on features not explicitly covered or narrowly claimed, or initiating post-grant review proceedings if prior art is identified.

For Innovators and R&D Teams

Understanding the scope of the '620 patent enables strategic innovation, ensuring new developments do not infringe while identifying opportunities to design around or improve upon patented features.


Key Takeaways

  • The '620 patent's claims balance specificity with breadth but may present enforceability challenges if broader claims are invalidated.
  • Its position within a dense patent ecosystem necessitates strategic freedom-to-operate assessments and potential licensing initiatives.
  • The patent’s influence on subsequent innovations underscores its importance but also highlights the potential for future legal contention.
  • Continuous monitoring of patent filings, citations, and legal developments in this domain is critical for maintaining competitive advantage.

Frequently Asked Questions (FAQs)

Q1: Can the '620 patent be licensed to third parties?
A: Yes. If the patent holder chooses to monetize its patent portfolio, licensing agreements can be negotiated, provided the patent’s claims are still enforceable and valid.

Q2: What are potential challenges to the validity of the '620 patent?
A: Challenges may stem from prior art references that predate the filing date or render the claims obvious, especially if similar technologies were publicly disclosed.

Q3: Is the '620 patent susceptible to design-around strategies?
A: Potentially. Competitors may modify specific claimed features to avoid infringement, particularly if certain claims are narrowly interpreted.

Q4: How does the patent landscape affect innovation in this area?
A: A crowded patent landscape can either spur innovation through licensing or hinder it via litigation risks, emphasizing the importance of strategic patent management.

Q5: Are there international equivalents of the '620 patent?
A: Likely. Major jurisdictions typically pursue corresponding filings, but the scope and validity may differ depending on local patent laws and prior art.


References

  1. [1] United States Patent and Trademark Office. Patent No. 9,085,620.
  2. [2] [Relevant prior art references, citation in the patent or known literature].
  3. [3] Industry reports or patent statistics databases (e.g., Patentscope, PatentScope, or Derwent).

This analysis aims to inform business decision-making by providing an authoritative assessment of the '620 patent’s claims and position within its patent landscape.

More… ↓

⤷  Get Started Free

Details for Patent 9,085,620

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Get Started Free 2035-04-08
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Get Started Free 2035-04-08
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Get Started Free 2035-04-08
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 ⤷  Get Started Free 2035-04-08
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 ⤷  Get Started Free 2035-04-08
Abbvie Inc. HUMIRA adalimumab Injection 125057 March 09, 2016 ⤷  Get Started Free 2035-04-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,085,620

Country Patent Number Estimated Expiration
South Africa 201006269 ⤷  Get Started Free
South Africa 200810349 ⤷  Get Started Free
South Africa 200608097 ⤷  Get Started Free
South Africa 200502983 ⤷  Get Started Free
South Africa 200500068 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2008150490 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.